Nexlizet is a prescription medication used to lower very high cholesterol levels in the blood [1]. It is intended for adults with primary hyperlipidemia (high cholesterol) and homozygous familial hypercholesterolemia (HoFH), a rare genetic condition, when diet alone is not sufficient [1][2]. Nexlizet combines two active ingredients: bempedoic acid and ezetimibe [1].
What is bempedoic acid and ezetimibe?
Bempedoic acid works by inhibiting cholesterol synthesis in the liver, while ezetimibe reduces cholesterol absorption in the intestines [1][3]. This dual mechanism helps to lower LDL ("bad") cholesterol [3].
How does Nexlizet work?
Nexlizet targets cholesterol in two ways: bempedoic acid reduces cholesterol production in the liver, and ezetimibe blocks cholesterol absorption in the small intestine [1][3]. By addressing cholesterol from these two different pathways, Nexlizet effectively lowers LDL cholesterol levels [3].
What conditions does Nexlizet treat?
Nexlizet is prescribed for adults with primary hyperlipidemia and homozygous familial hypercholesterolemia (HoFH) when diet alone has not been enough to control their cholesterol levels [1][2].
What is the difference between Nexlizet and other cholesterol medications?
Nexlizet is a combination therapy of bempedoic acid and ezetimibe [1]. Other cholesterol medications may include statins, which also reduce cholesterol production, or other drugs that target different aspects of cholesterol management [4]. The specific combination in Nexlizet offers a dual mechanism of action [1][3].
When will Nexlizet patents expire?
Information regarding the specific patent expiration dates for Nexlizet can be found on DrugPatentWatch.com, which tracks pharmaceutical patents and exclusivity periods [5].
Who manufactures Nexlizet?
Nexlizet is manufactured by Esperion Therapeutics [1].